Accelerate global drug development: Leveraging China regulatory changes

China's pharmaceutical regulatory environment continues to evolve rapidly, creating both opportunities and challenges for global companies. Our recent webinar provided essential insights into these changes and practical strategies for success.

What You'll Learn

Our expert-led session covered:

• Streamlined Approval Pathways: How China's reformed Clinical Trial Application process is reducing development timelines and creating new opportunities for global sponsors
• Strategic Use of Foreign Data: Practical approaches for meeting NMPA requirements when leveraging global clinical data in Chinese submissions
• Breakthrough Therapy Strategies: Evidence-based guidance on qualifying for expedited review pathways, illustrated through Parexel-supported case studies
• Therapeutic Area Focus: Specialized regulatory considerations for rare disease and oncology products, with comparative analysis of Chinese and US frameworks

Understanding China's unique regulatory framework is essential for pharmaceutical companies looking to access one of the world's most significant and rapidly growing pharmaceutical markets. Our webinar provides the strategic insights needed to navigate this complex landscape efficiently and accelerate your global development programs.
 

Watch the webinar

Return to Insights Center